Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR3006-1 + BR3006-2
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR3006-1 + BR3006-2 is an **investigational combination of two small molecule drugs** under development by Boryung Corp. The combination is currently being evaluated in early-phase clinical studies in healthy volunteers to assess drug-drug interactions and safety[1][2]. The individual identities, mechanisms of action, and their specific therapeutic targets have not been publicly disclosed as of the latest available data. Initial development appears focused on metabolic and endocrine indications, including type 2 diabetes mellitus[2]. No detailed mechanism, target, or ingredient information has been published.
- Other names
- BR3006-1 + BR3006-2
Beyond the preview
Go deeper on BR3006-1 + BR3006-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR3006-1 + BR3006-2.